Abstract:Abstract Most cancer target and biomarker studies focus on the identification of overexpressed genes or proteins of cancer cells. However, their potential feasibility as tumor-specific antigens targeted by antibody-guided nanomedicine has not consistently been based on quantitative assessments of tumor specificity and binding strength. Cancer cell membrane surfaces possess hundreds of different functionally versatile proteins (receptors and ligands) which are heterogeneously upregulated or downregulated to promote cancer development and progression. Selection of appropriate drug targets is pivotal to the successful development of tumor-targeted therapeutics because tumor-specific affinity of potential cancer targets is a key factor modulating cellular binding and uptake, and has the potential to translate to therapeutic bioactivity. To date, the quantitative measurements of cancer target antibody-antigen interactions are often limited by dynamic biophysical and biomechanical methods for probing such interactions. To address this challenge, we used flow cytometric analyses to compare 40 potential cancer cell surface target candidates for triple negative breast cancer (TNBC), an aggressive malignancy with limited treatment options. We selected intercellular adhesion molecule-1 (ICAM-1) as the “optimized” TNBC target for nanomedicine. Reasoning that adhesion forces between the ICAM-1 antibody and live human breast cancer cells could be used to guide nanomedicine delivery to TNBC tumors, we used atomic force microscopy (AFM) to evaluate the binding strength between the ICAM-1 antibody and antigen on live human TNBC cells and non-neoplastic cells. Adhesion forces between the ICAM-1 antibody and live human TNBC MDA-MB-231 cells (523 ± 113 pN) were significantly higher than those of non-neoplastic MCF10A cells (336 ± 33 pN). We next validated these findings by engineering ICAM-1-targeted immunoliposomes and then tested their TNBC-specific binding affinity and cytotoxicity on three TNBC cell lines. In vivo imaging experiments further confirmed that the ICAM-1-targeted immunoliposomes preferentially accumulated in orthotopic TNBC tumors, in comparison with nonspecific, IgG-conjugated liposomes. These data support the conclusion that ICAM-1 antibody-conjugated immunoliposomes containing chemotherapeutic drugs have the potential to preferentially target and destroy TNBC cells, and may also be applicable to a range of metastatic cancers that demonstrate an overexpression of ICAM-1. These findings also support the use of AFM as a valuable tool in the characterization of surface antigen-antibody interactions that predict in vitro and in vivo binding affinity. Acknowledgements: D. Auguste acknowledges the support of NIH 1DP2CA174495. M. Moses acknowledges the support of NIH R01CA185530 and the Breast Cancer Research Foundation. Citation Format: Peng Guo, Biran Wang, Daxing Liu, Jiang Yang, Marsha Moses, Debra Auguste. Using AFM to predict the specificity of tumor targeting nanomedicine in vivo. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2207.

Detecting the Micro/nano Physical Properties of Single Lymphoma Cells with Atomic Force Microscopy

AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells

Atomic Force Microscopy for Tumor Research at Cell and Molecule Levels

Atomic force microscopy as a nanomechanical tool for cancer liquid biopsy

Abstract 2207: Using AFM to Predict the Specificity of Tumor Targeting Nanomedicine in Vivo

Using Afm To Predict The Specificity Of Tumor Targeting Nanomedicine In Vivo

Microfluidic chip for non-invasive analysis of tumor cells interaction with anti-cancer drug doxorubicin by AFM and Raman spectroscopy

Machine Learning-Assisted CellIdentification Based on Ion CurrentFingerprints of Single Cells at Theorifice of a Nanopipette

Nanoscale Detection of Carbon Dots-Induced Changes in Actin Skeleton of Neural Cells

Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma

Atomic force microscopy for revealing micro/nanoscale mechanics in tumor metastasis: from single cells to microenvironmental cues

Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy

Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma

Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy

Enhanced Leukemia Cell Detection Using a Novel Magnetic Needle and Nanoparticles

Bio-Afm Of Cancer Cells And Multifunctional Theranostics

Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies

Atomic force microscopy-based assessment of multimechanical cellular properties for classification of graded bladder cancer cells and cancer early diagnosis using machine learning analysis

Study and Applications of Atomic Force Microscopy in the Cancer Cells

Abstract 4432: Molecular biomarkers of non-Hodgkin lymphomas and subtypes identified by mass spectrometry-based metabolomics